The antibody conjugated nanoliposome showed a faster and better uptake of them by MCF-7 (estrogen receptor-positive) cancer cells as compared to the treatment of the MDA-MB-453 (estrogen receptor-negative) cancer cells, indicating preferential uptake and suggesting the possibility of their success in the breast cancer cell targeting. This evidence concerns the gene ESR1 and breast cancer.